Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 open-label study of CNTO 888 monotherapy in recurrent ovarian cancer
2009-011250-17Phase 2Completed
- Sponsor
- Janssen Biotech
- Start
- Dec 2009
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of carlumab in ovarian cancer, sponsored by Janssen Biotech. Primary endpoint: Composite response rate. Started Dec 2009; status: completed.
02
Drugs
carlumab
03
Conditions
ovarian cancer
Beyond the preview
Go deeper on 2009-011250-17.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2009-011250-17.